Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown. Among 1880 children with ALL, 75 (4%) had losses involving chromosome 7, 16 (21%) with monosomy 7, 41 (55%) with losses of 7p (del(7p)), 16 (21%) with losses of 7q (del(7q)), and two (3%) with losses involving both arms. Patients with losses involving chromosome 7 were more likely to be X10 years old, National Cancer Institute (NCI) poor risk, and hypodiploid than patients lacking this abnormality. Patients with or without these abnormalities had similar early response to induction therapy. Event-free survival (EFS) and survival for patients with monosomy 7 (Po0.0001 and P ¼ 0.0007, respectively) or del(7p) (Po0.0001 and P ¼ 0.0001, respectively), but not of patients with del(7q), were significantly worse than those of patients lacking these abnormalities. The poorer EFS was maintained after adjustment for a Philadelphia (Ph) chromosome, NCI risk status, ploidy, or an abnormal 9p. However, the impact on survival was not maintained for monosomy 7 after adjustment for a Ph. These results indicate that the critical region of loss of chromosome 7 in pediatric ALL may be on the p-arm.
Introduction
Complete or partial loss of chromosome 7, predominantly monosomy 7 or deletions of 7q, is associated with a variety of myeloid disorders, including cases of preleukemic myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) in children 1 and de novo and therapy-related MDS and AML in adults. 2 Monosomy 7 or deletion of 7q in these disorders is associated with poor prognosis. [3] [4] [5] [6] It has been hypothesized that there is a tumor suppressor gene (TSG) on chromosome arm 7q that contributes to the pathogenesis of these diseases, and several chromosomal bands have been identified that contain commonly deleted segments, including 7q22 and different nonoverlapping regions in 7q31-q35. [7] [8] [9] [10] However, a putative TSG has not yet been identified on 7q. Childhood monosomy 7, or 'monosomy 7 syndrome', is a unique disorder that frequently progresses to AML, with poor outcome. 1 It may be associated with an array of genetic disorders including Fanconi anemia, neurofibromatosis type 1, severe congenital neutropenia, and Schwachman-Diamond syndrome. Chromosome 7 deletions and monosomy 7 have also been reported in adult acute lymphoblastic leukemia (ALL), in which they frequently occur as secondary aberrations associated with a Philadelphia (Ph) chromosome and predict a poor prognosis. 11 However, losses of chromosome 7 are not predictive of a worse prognosis when Ph-positive patients are excluded from the analyses. 11 Although generally infrequent in childhood ALL, monosomy 7 or structural abnormalities resulting in the deletion of 7p have been reported to confer increased risk of treatment failure in Ph-positive cases, and it has been hypothesized that a TSG on 7p may contribute to the poor outcome of these patients. 12 The significance of chromosome 7 losses, including monosomy 7, deletions of 7p, and deletions of 7q, in the overall population of children with ALL is unknown. Therefore, we have analyzed a large cohort of 1880 children with ALL treated on recent risk-adjusted trials of the Children's Cancer Group (CCG) for losses of all or part of chromosome 7.
Materials and methods

Patients
Diagnosis of ALL required determination of lymphoblastic morphology by Wright-Giemsa staining of bone marrow smears, negative lymphoblast staining for myeloperoxidase, and cell surface expression of two or more lymphoid differentiation antigens. 13 Immunophenotyping was performed centrally in the CCG ALL Biology Reference Laboratory by immunofluorescence and flow cytometry, as described previously. 13, 14 Patients were classified as B-lineage if X30% of their leukemic cells were positive for CD19 and/or CD24 and o30% were positive for one or more of the T-cell-associated antigens CD2, CD3, CD5, or CD7. Likewise, patients were classified as having T-lineage ALL if X30% of the isolated blasts were positive for one or more of the T-cell-associated antigens CD2, CD3, CD5, or CD7 and o30% were positive for CD19 and/or CD24.
The current study involved 4986 children entered in CCG risk-adjusted ALL protocols between 1988 and 1995. Children aged 2-9 years with white blood cell (WBC) counts o10 000/ml were treated on CCG-1881 for low-risk patients, 15 and children aged 2-9 years with WBC counts 10 000-49 999/ml or aged 12-24 months and WBC counts o50 000/ml were enrolled on CCG-1891 for intermediate-risk patients. 16 After completion of these studies, children with low-or intermediate-risk ALL were enrolled on CCG-1922. 17 High-risk patients (age X10 years and/or with WBC counts X50 000/ml) were treated on CCG-1882 18, 19 or CCG-1901, for patients with multiple unfavorable features (lymphomatous syndrome). 20 Infants aged o1 year were excluded from this analysis. All protocols were approved by the National Cancer Institute (NCI) and the institutional review boards of the participating CCG-affiliated institutions. Informed consent was obtained from parents, patients, or both, in accordance with the Declaration of Helsinki.
Cytogenetic analysis
Cytogenetic analyses were performed at diagnosis by institutional laboratories. A minimum of two original karyotypes from each abnormal clone were reviewed centrally by at least two members of the CCG Cytogenetics Committee. Abnormalities were designated using the International System for Human Cytogenetic Nomenclature (ISCN, 1995) . 21 Abnormal clones were defined as two or more metaphase cells with identical structural abnormalities or extra chromosomes, or three or more metaphase cells with identical missing chromosomes. Acceptance of a normal karyotype required analysis of a minimum of 20 cells from unstimulated bone marrow only. A total of 1880 cases had centrally reviewed and accepted cytogenetic data; 75 (4%) had losses of all or part of chromosome 7.
Statistical methods
Data were current to August 31, 2001 . Clinical, demographic, and laboratory features of patients with and without deletions of chromosome 7 were compared using w 2 tests for homogeneity of proportions. Outcome was analyzed using life table methods and associated statistics. The primary end point examined was event-free survival (EFS) from study entry; events included induction failure (nonresponse to therapy or death during induction), leukemic relapse at any site, death during remission, or second malignant neoplasm, whichever occurred first. Patients who did not have an event at the time of EFS analysis were censored at the time of last contact. The Kaplan-Meier life 23, 24 P-values are based on the pattern of outcome across the entire period of patient follow-up; values p0.05 are referred to as statistically significant.
The current cohort of patients with accepted cytogenetic data was similar to concurrently enrolled patients who did not have accepted cytogenetic data with respect to many presenting features, although patients with accepted data were more likely to be white, have high WBC counts, high platelet and hemoglobin levels, large mediastinal masses, lymphadenopathies, T-lineage immunophenotypes, and non-L1 FAB morphologies. The actual percentages of patients with or without accepted cytogenetic data in these categories, however, did not appear to differ; thus, the statistical differences may be due to the large sample size. Early treatment response, induction outcome, and EFS were nearly identical for concurrently enrolled patients with or without accepted cytogenetic data.
Results
Cytogenetic features of children with ALL and complete or partial losses of chromosome 7
Complete or partial losses of chromosome 7 were found in 75 of 1880 (4%) childhood ALL patients with accepted cytogenetics after review. Full karyotypes of children with ALL and losses involving chromosome 7 are given in Table 1 , and the losses are shown graphically in Figure 1 . More than half (N ¼ 59; 79%) of these patients had loss of the p-arm of chromosome 7, including 16 with monosomy 7, 41 with structural rearrangements resulting in deletions of 7p, and two with losses of both 7p and 7q. (Note: Losses of 7p that extended into 7q11.2 were considered as 7p losses.) In all, 12 cases with loss of 7p had an i(7)(q10), and five had -7,der(v)t(v;7)(v;q11.2), where 'v' is any chromosome. Although no consistent region of loss was identified, most 7p losses included p15-pter ( Figure 1 ). Losses involving the q-arm of chromosome 7 occurred in 34 cases (45%) including 16 with monosomy 7 and two with losses of both 7p and 7q, and most losses included 7q32-qter. Hypodiploidy (N ¼ 27) and pseudodiploidy (N ¼ 27) were more frequent than low hyperdiploidy (47-50 chromosomes; N ¼ 9) or high hyperdiploidy (450 chromosomes, HH; N ¼ 12) among the patients with losses involving chromosome 7 (Table 2) . However, losses of the p-arm of chromosome 7 occurred with similar frequencies in hyperdiploid, pseudodiploid, and HH karyotypes; whereas losses involving the q-arm of chromosome 7 were most frequent in patients with pseudodiploidy. Of the 16 cases with monosomy 7, 12 were hypodiploid. Only one of the 11 HH (one patient was near-tetraploid) patients had trisomy of chromosomes 4, 10, and 17, identified as associated with a superior outcome in Children's Oncology Group (COG) studies (unpublished COG data 31, 32 ). Of the 75 patients, 72 (96%) had structural abnormalities. Only one patient had a sole abnormality, monosomy 7. A high percentage of patients with losses involving chromosome 7 also had an abnormal 9p (N ¼ 27; 36%) and/or an abnormal 12p (N ¼ 16; 21%). Five patients had a Philadelphia (Ph) chromosome: three with monosomy 7 and two with del(7p). A t(1;19) was present in six patients, five with an unbalanced der(19)t (1;19) . No patient had a t(4;11).
Comparison of clinical and biological characteristics of children with ALL with or without losses involving chromosome 7
The clinical and biological characteristics at diagnosis of ALL in children with losses involving chromosome 7 were compared with those without this abnormality (Table 2) . Patients with losses involving chromosome 7 were more likely than patients without this abnormality to be X10 years of age (P ¼ 0.004), to have NCI poor risk 33 status (P ¼ 0.002), a t(1;19) translocation (P ¼ 0.03), or a Ph chromosome (P ¼ 0.01). Patients with losses involving chromosome 7 were more likely to have hypodiploidy and less likely to have HH (Po0.0001) than patients without losses involving chromosome 7. Leukemic cells from patients with losses involving chromosome 7 were no more likely than those without this abnormality to express the myeloid markers CD13 (P ¼ 0.73) or CD33 (P ¼ 0.30).
Response to induction therapy of children with ALL and losses involving chromosome 7
Early marrow status (blasts percentage on day 7 of induction therapy), which is a significant prognostic factor for ALL patients, 34 was not significantly different for patients with or without losses involving chromosome 7 (P ¼ 0.15), although a lower percentage of patients with (39%) versus without (50%) losses involving chromosome 7 had M1 marrow status (o5% blasts). A higher frequency of patients with losses involving Table 3 ). Patients with a loss involving chromosome 7 had higher frequencies of both marrow and central nervous system relapses than patients without this aberration. The poorer EFS and OS were retained when Ph patients were excluded from the analyses (Po0.0001 for both comparisons), after adjustment for NCI risk status (Po0.0001 for both comparisons) and after adjustment for ploidy (P ¼ 0.0002 and 0.004, respectively; Table 3 ). An abnormal 9p in this overall cohort of 1880 patients was associated with a poor prognosis. 35 After adjustment for an abnormal 9p, EFS and OS maintained significance (Po0.0001 and P ¼ 0.0001, respectively). The poorer outcome was maintained when Ph patients were excluded from the adjusted analyses (Table 3) .
Outcome of children with ALL and monosomy 7, deletions of 7p, and deletions of 7q
To determine if monosomy 7 conferred a different prognostic risk than deletions of 7p (del(7p)) and deletions of 7q (del(7q)), outcome for patients with monosomy 7 (16 patients), patients with del(7p) only (41 patients, including those with breakpoints in 7q11.2), and patients with del(7q) only (16 patients, including patient 66 with near-tetraploidy and loss of 7q in two chromosomes 7) was analyzed. Patients 74 and 75 were omitted from these analyses as they had deletions of both 7p and 7q. Patients with monosomy 7 had a worse EFS and OS than patients lacking this abnormality (Po0.0001 and P ¼ 0.0007, respectively; Table 3 ; Figures 2 and 3) . The difference in EFS was maintained when the analyses were adjusted for the presence of a Ph (P ¼ 0.008), NCI risk status including (P ¼ 0.0007) and excluding (P ¼ 0.03) Ph patients, ploidy when Ph patients were included (P ¼ 0.01), and an abnormal 9p including (P ¼ 0.002) and excluding (P ¼ 0.04) Ph patients. However, the worse OS was not maintained when Ph patients were excluded from the adjusted analyses (Table 3) . Significantly, EFS and OS were significantly worse for patients with del(7p) than for patients with normal 7p (Po0.0001 and P ¼ 0.0001, respectively; Table 3 ; Figures 2  and 3) . Moreover, these differences were maintained when the analyses were adjusted for a Ph chromosome (Po0.0001 and P ¼ 0.0004, respectively), NCI risk status including (Po0.0001 and P ¼ 0.0004, respectively) and excluding (P ¼ 0.0001 and 0.001, respectively) Ph cases, ploidy including (P ¼ 0.004 and 0.01, respectively) and excluding (P ¼ 0.003 and 0.01, respectively) Ph cases, and an abnormal 9p including (P ¼ 0.0007 and 0.004, respectively) and excluding (P ¼ 0.0005 and 0.004, respectively; Table 3 ) Ph cases. However, outcome for patients with deletions of 7q but with apparently normal 7p's was not significantly different from that of patients lacking this abnormality in any of the analyses (Table 3 ; Figures 2 and 3 ).
Discussion
We have examined the frequency and prognostic significance of losses and deletions of chromosome 7 in a large cohort of children with ALL. Loss of all or part of chromosome 7 was found in 75 of 1880 (4%) patients studied. Unlike adults with ALL and losses involving chromosome 7, 11 children with losses involving chromosome 7 in this cohort were not more likely than those without this abnormality to express myeloid markers.
Dabaja et al 11 found no difference in survival rates for adult ALL patients with or without deletions of chromosome 5 or 7; both groups, however, had a very poor outcome (3-year survival of approximately 36%). Monosomy 7 and del(7q) have been associated with an adverse outcome in AML, [3] [4] [5] [6] suggesting that the critical region(s) in AML may be in the q-arm. [7] [8] [9] [10] In this study, both EFS and OS were significantly worse for children with ALL with a loss involving chromosome 7 than for patients lacking this abnormality. However, when the patients were grouped by those with monosomy 7, deletions of 7p resulting from structural rearrangements, and deletions of 7q resulting from structural rearrangements, only deletions of 7p were consistently associated with an inferior outcome. Additionally, children with ALL with a loss involving chromosome 7 were more likely than patients without this abnormality to be of age 10 or greater, have NCI poor risk status, have a Ph chromosome, hypodiploidy and/or have an abnormal 9p, all adverse risk factors in this cohort of children with ALL. 25, 26, 32, 33 After adjustment for each of these features, the poorer EFS and OS of children with del(7p) were maintained, indicating that del(7p) is a significant adverse prognostic factor regardless of the presence of other adverse risk factors. Patients with monosomy 7 also had a worse EFS, which was maintained after adjustment for each of these factors including and excluding Ph patients except when the analysis was adjusted for ploidy and Ph patients were excluded from the analysis. However, monosomy 7 did not confer a worse OS when patients with a Ph were excluded from the analyses nor when the analyses were adjusted for ploidy and Ph patients were included in the analysis, although a difference was suggested for the latter (P ¼ 0.06). Importantly, patients with deletions of 7q did not have a significantly worse EFS or OS compared with patients with no losses involving chromosome 7, with or without adjustment for other features. These results suggest that the critical region of loss of chromosome 7 that is associated with an inferior outcome in childhood ALL may be located on the p-arm. Russo et al 12 suggested that a tumor suppressor gene on 7p might contribute to the poor outcome of children with Ph ALL and monosomy 7 or losses involving 7p. Our results are consistent with this hypothesis, and extend the significance of loss of 7p to Ph-negative childhood ALL. Thus although losses involving chromosome 7 are associated with a poor prognosis in both ALL and AML, the critical region of chromosome 7 may differ.
Conclusion
Losses involving chromosome 7 are relatively frequent in childhood ALL. Deletions of 7p confer an inferior outcome in children with ALL, regardless of the presence of other poor prognostic features, whereas deletions of 7q are not associated with a worse outcome. Monosomy 7 is also associated with an inferior EFS in children with ALL, except when the analysis is adjusted for ploidy and Ph patients are excluded. Monosomy 7 and del(7p) in childhood ALL appear to represent a form of leukemia distinct from monosomy 7 and losses involving chromosome arm 7q observed in myeloid disorders in children or adults. OS for childhood ALL patients with monosomy 7, deletions of 7p, and deletions of 7q. The 7-year OS estimates were 56% (s.d. ¼ 12%) for patients with monosomy 7, 60% (s.d. ¼ 8%) for patients with del(7p), 79% (s.d. ¼ 11%) for patients with del(7q), and 84% (s.d. ¼ 1%) for patients without del(7) (Po0.0001).
